Metformin diminishes the unfavourable impact of Nrf2 in breast cancer patients with type 2 diabetes
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a major regulator of the oxidative stress response and it is negatively regulated by Kelch-like ECH-associated protein 1 (Keap1). The Keap1–Nrf2 axis has a fundamental role in carcinogenesis. In previous studies, the widely used diabetes drug met...
Saved in:
| Main Authors: | Elina Urpilainen, Jenni Kangaskokko, Ulla Puistola, Peeter Karihtala |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-01-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428318815413 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
How to choose optimal adjuvant therapies for high-risk hormone receptor-positive, HER2-negative breast cancer after chemotherapy?
by: Peeter Karihtala
Published: (2025-06-01) -
Multidimensional effects of metformin in patients with type 2 diabetes
by: Lyudmila A. Ruyatkina, et al.
Published: (2017-08-01) -
Metformin Enhances the Chemosensitivity of Gastric Cancer to Cisplatin by Downregulating Nrf2 Level
by: Guihua Duan, et al.
Published: (2025-01-01) -
Enhancing Diabetes Treatment: Comparing Pioglitazone/Metformin with Dapagliflozin Versus Basal Insulin/Metformin in Type 2 Diabetes
by: Lin Y, et al.
Published: (2025-03-01) -
NRF2 ACTIVATOR DIMETHYL FUMARATE DIMINISHED STEATOSIS, INFLAMMATION AND LIPID PEROXIDATION IN THE LIVER OF BINGE ETHANOL-TREATED RATS
by: İlknur Bingül, et al.
Published: (2024-01-01)